JP2022545287A - Ｂｃｎ０５７及びｂｃｎ５１２を用いる治療方法 - Google Patents

Ｂｃｎ０５７及びｂｃｎ５１２を用いる治療方法 Download PDF

Info

Publication number
JP2022545287A
JP2022545287A JP2022512449A JP2022512449A JP2022545287A JP 2022545287 A JP2022545287 A JP 2022545287A JP 2022512449 A JP2022512449 A JP 2022512449A JP 2022512449 A JP2022512449 A JP 2022512449A JP 2022545287 A JP2022545287 A JP 2022545287A
Authority
JP
Japan
Prior art keywords
fibrosis
formula
day
cancer
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022512449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545287A5 (enExample
Inventor
ノーリス，アンドリュー
チャクラボルティ，スディップ
Original Assignee
ビーシーエヌ バイオサイエンシズ エル．エル．シー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビーシーエヌ バイオサイエンシズ エル．エル．シー． filed Critical ビーシーエヌ バイオサイエンシズ エル．エル．シー．
Publication of JP2022545287A publication Critical patent/JP2022545287A/ja
Publication of JP2022545287A5 publication Critical patent/JP2022545287A5/ja
Priority to JP2024212337A priority Critical patent/JP2025032222A/ja
Priority to JP2026089220A priority patent/JP2026127687A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022512449A 2019-08-24 2020-08-24 Ｂｃｎ０５７及びｂｃｎ５１２を用いる治療方法 Pending JP2022545287A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024212337A JP2025032222A (ja) 2019-08-24 2024-12-05 Ｂｃｎ０５７及びｂｃｎ５１２を用いる治療方法
JP2026089220A JP2026127687A (ja) 2019-08-24 2026-05-27 Ｂｃｎ０５７及びｂｃｎ５１２を用いる治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962891338P 2019-08-24 2019-08-24
US62/891,338 2019-08-24
PCT/US2020/047692 WO2021041347A1 (en) 2019-08-24 2020-08-24 Methods of treatment using bcn057 and bcn512

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024212337A Division JP2025032222A (ja) 2019-08-24 2024-12-05 Ｂｃｎ０５７及びｂｃｎ５１２を用いる治療方法

Publications (2)

Publication Number Publication Date
JP2022545287A true JP2022545287A (ja) 2022-10-26
JP2022545287A5 JP2022545287A5 (enExample) 2023-10-25

Family

ID=74647168

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022512449A Pending JP2022545287A (ja) 2019-08-24 2020-08-24 Ｂｃｎ０５７及びｂｃｎ５１２を用いる治療方法
JP2024212337A Pending JP2025032222A (ja) 2019-08-24 2024-12-05 Ｂｃｎ０５７及びｂｃｎ５１２を用いる治療方法
JP2026089220A Pending JP2026127687A (ja) 2019-08-24 2026-05-27 Ｂｃｎ０５７及びｂｃｎ５１２を用いる治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024212337A Pending JP2025032222A (ja) 2019-08-24 2024-12-05 Ｂｃｎ０５７及びｂｃｎ５１２を用いる治療方法
JP2026089220A Pending JP2026127687A (ja) 2019-08-24 2026-05-27 Ｂｃｎ０５７及びｂｃｎ５１２を用いる治療方法

Country Status (6)

Country Link
US (2) US11358964B2 (enExample)
EP (1) EP4017493A4 (enExample)
JP (3) JP2022545287A (enExample)
CN (1) CN114728001A (enExample)
AU (2) AU2020337892B2 (enExample)
WO (1) WO2021041347A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118541368A (zh) * 2021-09-03 2024-08-23 比西恩生物科学有限责任公司 使用bcn057、bcn077及类似物的治疗方法
US20240122916A1 (en) * 2022-10-08 2024-04-18 Radmit, Inc. Effect of YEL002 on Conditions and Diseases
US20240325375A1 (en) * 2023-04-01 2024-10-03 Radmit, Inc. Effect of YEL002 on Psychological and Psychiatric Factors in Health and Disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100173930A1 (en) * 2006-08-01 2010-07-08 Alex Muci Certain Chemical Entities, Compositions and Methods
US20180104233A1 (en) * 2016-10-16 2018-04-19 BCN Biosciences L.L.C. Methods of treatment and pharmaceutical compositions using bcn057 or bcn512
WO2019075402A1 (en) * 2017-10-12 2019-04-18 University Of Kansas METHODS FOR TREATING GASTROINTESTINAL SYNDROME INDUCED BY RADIATION

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
AU2018316185A1 (en) * 2017-08-08 2020-03-26 BCN Biosciences L.L.C. Methods of treating radiation induced gastrointestinal syndrome (RIGS) and related disease states using compound 512

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100173930A1 (en) * 2006-08-01 2010-07-08 Alex Muci Certain Chemical Entities, Compositions and Methods
US20180104233A1 (en) * 2016-10-16 2018-04-19 BCN Biosciences L.L.C. Methods of treatment and pharmaceutical compositions using bcn057 or bcn512
WO2019075402A1 (en) * 2017-10-12 2019-04-18 University Of Kansas METHODS FOR TREATING GASTROINTESTINAL SYNDROME INDUCED BY RADIATION

Also Published As

Publication number Publication date
AU2020337892A1 (en) 2022-05-19
US11358964B2 (en) 2022-06-14
CN114728001A (zh) 2022-07-08
AU2025267506A1 (en) 2025-12-11
JP2025032222A (ja) 2025-03-11
AU2020337892B2 (en) 2025-08-14
WO2021041347A1 (en) 2021-03-04
US20230035771A1 (en) 2023-02-02
EP4017493A4 (en) 2023-08-23
JP2026127687A (ja) 2026-08-06
US20210053968A1 (en) 2021-02-25
EP4017493A1 (en) 2022-06-29
US12435081B2 (en) 2025-10-07

Similar Documents

Publication Publication Date Title
JP6823095B2 (ja) 噴霧乾燥製剤
US12435081B2 (en) Methods of treatment using BCN057 and BCN512
WO2020259528A1 (zh) 治疗特发性肺纤维化的方法
BRPI0712938A2 (pt) mÉtodo para modular excrescÊncia de neurito pelo uso de um antagonista de receptor de galanina-3
KR20210102887A (ko) 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
US20180162827A1 (en) Radiomitigating pharmaceutical formulations
JP2025081626A (ja) ペンタミジンの類似体及びその使用
CA2608171C (en) Use of quinolinone compounds for treating drug resistant cancers
AU2018346962A1 (en) Methods of treating radiation induced gastrointestinal syndrome
US20240376098A1 (en) Methods of treatment using bcn057, bcn077 and analogs
KR20250046197A (ko) 티오벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis
CN120569196A (zh) 用于控制葡萄糖水平的组合物和方法
WO2017156222A1 (en) Radiomitigating compounds, compositions and methods related thereto

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231017

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240806